Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

Stiefel Laboratories to Take Over Barrier Therapeutics for $148M

  • Stiefel Laboratories intends to acquire Barrier Therapeutics for approximately $148 million to bolster its dermatology franchise. Stiefel is offering $4.15 per share in cash, a 135% premium over Barrier Therapeutics’ previous day closing price. Barrier Therapeuctics’ stock went from $1.76 at close on Friday to open today at $3.99.

    The transaction is expected to close by the end of the third quarter. Stiefel Laboratories will gain three marketed drugs. In addition, Barrier Therapeutics will bring with it five candidates in various stages of clinical development.

    “This acquisition demonstrates our continued commitment to advancing the field of therapeutic dermatology,” comments Charles W. Stiefel, chairman and CEO of Stiefel Laboratories. “We are very impressed with Barrier Therapeutics’ innovative products and pipeline. This strategic move will further expand our oral and topical product portfolio in development and increase our sales of novel treatments for skin conditions.”


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »